Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
0.9500
+0.0650 (7.34%)
Dec 3, 2025, 3:48 PM EST
Interpace Biosciences Employees
Interpace Biosciences had 111 employees as of December 31, 2024. The number of employees increased by 3 or 2.78% compared to the previous year.
Employees
111
Change (1Y)
3
Growth (1Y)
2.78%
Revenue / Employee
$377,613
Profits / Employee
$30,045
Market Cap
4.73M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| Zomedica | 152 |
Interpace Biosciences News
- 23 days ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 2 months ago - Interpace Biosciences (IDXG) Showcases Promising Thyroid Nodule Testing Advances - GuruFocus
- 2 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 4 months ago - Interpace Biosciences Earnings Drop - The Motley Fool
- 8 months ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 11 months ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 11 months ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 11 months ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire